Integra completes refinancing with $450 million notes and new $1.65 billion credit facility

what happened

Integra LifeSciences Holdings said it has closed a private offering of $450.0 million in 9.500% senior secured notes due 2033. At the same time, the company amended and restated its existing credit facility, with an overall size of about $1.65 billion, including a $600 million revolver and a $600 million term loan A, both maturing in five years, and a $450 million term loan B due in seven years.

Integra said it used the net proceeds, along with borrowings under the new facility, to refinance its existing credit line and cover fees and expenses. The notes were not registered under the Securities Act of 1933 and were offered only to qualified institutional buyers and certain non-U.S. persons.

why it matters

The deal pushes out the company's debt maturities while locking in a relatively high coupon, which matters for credit investors in medical technology. For the broader market, the event is routine.

market impact

Integra bonds: refinancing reduces near-term repayment risk, but the 9.5% coupon weighs on creditors' returns.

tags

instruments